Latest news and press releases about Corcept Therapeutics Incorporated (CORT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Price
| Price | $116.23 |
| Market Cap | $12.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 223.52 |
| Price / Book | 17.35 |
| EV / EBITDA | 433.39 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 8.37% |
| Return on Invested Capital | 0.87% |
| Return on Assets | 6.18% |
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Net Margin | 6.61% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks